26 Февраль,2003 | 7-я Междисциплинарная Региональная конференция по биологической психиатрии
Стресс и поведение
При поддержке International Brain Research Organisation (IBRO)
26-28 февраля 2003 г. в Москве состоится 7-я Междисциплинарная конференция по проблемам стрессорного поведения.
Цель ежегодной международной конференции, проводимой ЦФБП начиная с 1997 г собрать биологов, медиков и психологов из России и других стран СНГ для междисциплинарного обсуждения механизмов стрессорного поведения человека и животных в норме и патологии.
Темы конференции: нейрохимия и нейрофизиология поведения человека и животных, нейропсихофармакология, моделирование поведения, страх, тревога, депрессия, агрессия нейробиология и клинические аспекты, сон и его нарушения, механизмы памяти, психофизиология, нейропсихология, психиатрия, нейроэтология, этология человека
Подробная информация на веб-сайте конференции
Председатель конференции А.В.Калуев (Москва)
22 Февраль,2003 | FDA approves Prozac for use in children
LAHORE, Feb 20-PPI: Doctors can now prescribe the popular antidepressant Prozac to children suffering from depression and obsessive compulsive disorder, the US Food and Drug Administration has ruled, reports The HealthScout News Service. Pakistan Press International via NewsEdge Corporation : LAHORE, Feb 20-PPI: Doctors can now prescribe the popular antidepressant Prozac to children suffering from depression and obsessive compulsive disorder, the US Food and Drug Administration has ruled, reports The HealthScout News Service. The decision which covers children and teens seven to 17 years of age, marks the first approval of one of the newer types of antidepressants -called selective serotonin reuptake inhibitors, or SSRIs- or treating depression in children. Depression affects upto 25 per cent of children and about eight percent of teens in the United States. Obsessive Compulsive Disorder, or OCD, affects about tow percent o the population, and typically begins during adolescence or childhood. At least one-third of the cases of adult OCD begin in childhood, the National Institute of Mental Health says. Clinical trials revealed that the side effects of Prozac use in children and teens were similar to those typically experienced by adults, including nausea, tiredness, nervousness, dizziness, and difficulty concentrating, the FDA says. However, one trial in children and adolescents eight to 17 years old found that after 19 weeks of treatment with Prozac, the study participants gained, on average, about a half an inch less I height and about two pounds less in weight compared to children taking a placebo. The drug's maker, Eli Lilly, has agreed to conduct a follow up study to further evaluate any potential impact of Prozac's use on long-term growth in children, the FDA says. (THROUGH ASIA PULSE) 20-02 2003 <> << Copyright ©2003 Asia Pulse Pte Ltd. >>
20 Февраль,2003 | Cовременные аспекты клинической, экспертной и социальной проблем подростково-юношеской психиатрии
Программа постоянно действующего семинара по теме: "Современные аспекты клинической, экспертной и социальной проблем подростково-юношеской психиатрии" для психиатров, участвующих в военно-врачебной экспертизе, подростковых психиатров и психологов на 2003 год (восьмой год обучения)
19 Февраль,2003 | Sales of Antipsychotics and Anticonvulsants for the Bipolar Drug Market Will Reach $2.6 Billion in 2011
PR via NewsEdge Corporation : WALTHAM, Mass., Feb. 19 /PRNewswire/ -- Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, forecasts that sales of antipsychotics and anticonvulsants for the bipolar drug market will reach $2.6 billion in 2011; this figure will represent nearly 90% of the total bipolar disorder drug market. (Photo: http://www.newscom.com/cgi-bin/prnh/20000303/DECISION ) "Growth in the on- and off-label use of antipsychotics and anticonvulsants will be the key market driver for the bipolar disorder drug market from 2001 through 2011," said Timothy Gasperoni, Ph.D., analyst at Decision Resources. "These agents will expand the range of therapeutic options for the short- and long-term treatment of manic and depressive symptoms -- particularly for the estimated 30-50% of patients who are unable to tolerate or fail to respond to lithium, the current standard of care." The new Pharmacor study entitled Bipolar Disorder also finds that Bristol- Myers Squibb's Abilify (aripiprazole) will spur market growth. "Despite its limited regulatory approval (i.e., for acute mania only) and its patent expiration in all markets in 2009, we expect Abilify to garner more than 11% of the bipolar disorder market in 2011," continued Dr. Gasperoni. Disease Background-Bipolar Disorder Bipolar disorder is a chronic and debilitating psychiatric illness characterized by recurrent episodes of aberrant mood. Mood episodes vary in duration among patients and feature symptoms of mania, depression, hypomania (a less severe form of mania), or a mixture of both depression and mania. Although more than 5 million people in the seven major pharmaceutical markets (United States, France, Germany, Italy, Spain, United Kingdom, and Japan) are afflicted with bipolar disorder, drug development for this indication has remained relatively stagnant. About Pharmacor from Decision Resources Pharmacor is a unique family of studies based on primary and secondary research conducted by Decision Resources' on-staff experts. Each comprehensive study assesses a host of market-impacting factors and analyzes the commercial outlook for drugs in research and development. Cardium, Cognos, Immune and Inflammatory Disorders, Infectious Disease, Metabolic Disorders, Psychiatric Disorders, and Onkos concentrate on specific therapeutic areas. Mosaic covers high-interest disease states. Bipolar Disorder is a Psychiatric Disorders study. About Decision Resources Decision Resources, Inc., is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. The company provides strategic information services, and assesses international pharmaceutical and health care industry trends. Visit Decision Resources at www.decisionresources.com. All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders. For more information, contact: Elizabeth Marshall Decision Resources, Inc. 781-296-2563 emarshall dresources.com SOURCE Decision Resources, Inc. -0- 02/19/2003 /CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-2563, emarshall dresources.com/ /Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20000303/DECISION AP Archive: http://photoarchive.ap.org PRN Photo Desk, 888-776-6555 or 212-782-2840/ CO: Decision Resources, Inc. ST: Massachusetts IN: MTC HEA PUB SU: SVY ES-CP -- NEW022 -- 5479 02/19/2003 10:37 EST http://www.prnewswire.com <> << Copyright ©2003 PR Newswire >>
18 Февраль,2003 | 5-HT 7 RECEPTOR ANTAGONISTS
Abstract: Amino-pyrimidine and amino-triazine derivatives having 5-HT 7 antagonist activity for the treatment of sleeping disorders, depression, schizophrenia, anxiety, obsessive compulsive disorders, circadian rhythm disorders, ocular disorders and/or centrally and peripherally mediated hypertension are provided. European Patents via NewsEdge Corporation : Abstract: Amino-pyrimidine and amino-triazine derivatives having 5-HT 7 antagonist activity for the treatment of sleeping disorders, depression, schizophrenia, anxiety, obsessive compulsive disorders, circadian rhythm disorders, ocular disorders and/or centrally and peripherally mediated hypertension are provided. Pub. No.: EP 1280781 Appl. Data: EP 01928857 2001 04 25 If you would like to purchase a copy of this patent, please call MicroPatent at 800-648-6787. Applicant: Bristol-Myers Squibb Co. << Copyright ©2003 MicroPatent >>
17 Февраль,2003 | Some 8.4 million of country's population afflicted by Depression
Some 8.4 million of country's population afflicted by Depression Karachi Feb 15 : Owing to its disabilities and cost burden for affected families, depression has been identified, in recent period of time, as a major serious health issue, tormenting some 8.4 million of country's population which constitutes 6 % of the total ratio and incurring heavy economic burden on the sufferers. Pakistan Press International via NewsEdge Corporation : Karachi Feb 15 (PPI): Owing to its disabilities and cost burden for affected families, depression has been identified, in recent period of time, as a major serious health issue, tormenting some 8.4 million of country's population which constitutes 6 % of the total ratio and incurring heavy economic burden on the sufferers. Talking to PPI, Dr. Amin Gadet, Head of Psychology Department, Hamdard University while discussing the enormous economic stress of the problem informed that on account of huge cost of its burden in financial terms, an overwhelming majority of victims of the disease which is almost 3 % of the total sufferer, are unable to seek remedy of their problems besides adding to the misery of illness and loss of associated productivity. "The annual earmarking in national budget for the health sector is critically low and owing to the fact that average income of majority of the victims of the disease is far from satisfactory, the partial support from charitable organizations, public sector hospitals, insurance cover and medical facilities by organizations, can hardly cater to the medical requirements of needy patients". He underscored the need to enhance health budgets and increase efforts towards preventive strategies besides pursuing further research on health economics with generation of appropriate database by the government. "Depressive disorders, when afflict any individual, are under diagnosed and under treated and it transpired during successive experiments that inadequate diagnosis and treatment of depression are primarily responsible for most of the costs of these disorders". "Some 50 % to 60 % of the patients with significant depression are found to be inaccurately diagnosed and recent data available clearly suggested that only one in three people victimized by the disease, seek specific treatment for their condition while overwhelming number avoid defining themselves as depressed when they consult a health care provider" he added. Dr. Gadet opined that their condition is partly due to the fact that they perceive themselves as hopeless, unwilling to accept a diagnosis of depressive disorders and above all, are apprehensive of the stigmatization and loss of their jobs. "It was ironically also observed that many physicians are reluctant to diagnose patients as depressed and it was found in majority of the cases they often focussed their diagnosis and treatment efforts on patients accompanying physical symptoms which includes fatigue, weight loss, headache, gastrointestinal disorders, pains and sleep disorders rather than on depression". "Besides it was also noted that of the 2/3rd of depressed patients who specifically did not refer themselves for depression, 80 % were seen for other physical complaints and of these patients only, one in eight was correctly diagnosed by their primary care provider as suffering from depressive illness while significant depression often remained undiagnosed for years" he pointed out. While underlining multifarious complications associated with depression, Dr. Gadet said that investigations have clearly manifested that depression enhances medical utilization for a variety of somatic complaints, the most common being weakness, lethargy, headaches, backaches, insomnia and gastrointestinal disorders. "These complaints often produce unnecessary hospitalization, physicians visits, diagnostic tests and prescriptions for analgesics, anxiolytics, sedatives and gastrointestinal medications. They use emergency services three to four times and call about health problems and for medication changes four to five times more often than non- depressed enrollees". He lamented about the fact that there is a pressure to refer patients with psychiatric disorders to the lowest level of provider who can address their needs and to treat them in the least restrictive, most cost sensitive environment. Multiple barriers which often make no clear sense have been created to limit access to psychiatrists and psychiatric inpatient care. Talking about total cost of the depression suffered by the victims, he said out of the total patients 50 % do not seek treatment at any stage and this brings the figure of 4.2 million peoples who seek treatment. According to the calculation total cost of depression comes to around Rs. 1,56,600 per annum including direct cost of outpatient consultation, medication, service fees, laboratory, hospitalization and indirect cost which includes pre mature death of supporter temporal sick leave, handicap low productivity. When the above amount is multiplied with 42 hundred thousand patients, the amount comes to Rs. 632.5 billion which is equal to US $ 10.54 Billion ( 1 US $- Rs. 60 Pak. Rupees). Keeping in view the high economic cost burden incurred by individuals and the society, he emphasized the exigency that it is the high time that the government should seriously review and revise its health policy with appropriate and justifiable allocation of budget to cater for the mental health need of the society. (THROUGH ASIA PULSE) 15-02 2003 <> << Copyright ©2003 Asia Pulse Pte Ltd. >>
15 Февраль,2003 | Astra Zeneca seeks EU approval for Seroquel in manic depression.
Astra Zeneca has submitted an application for registration of Seroquel in 14 EU member states which participate in the mutual approvals procedure. Chemical Business NewsBase - Dagens Industri via NewsEdge Corporation : Astra Zeneca has submitted an application for registration of Seroquel (quetiapin) in 14 EU member states which participate in the mutual approvals procedure. The application is for an extension of the approval to include the treatment of manic episodes in manic depression and is based on a comprehensive programme of clinical studies in manic depressive patients aimed at determining efficacy and tolerance. The results from the study indicate that Seroquel has a pronounced positive effect both as a single therapy and in combination with other drugs (lithium or divalproex) and support the claim that Seroquel is an excellent treatment of first choice. Applications for extended approval are planned for other markets throughout the world. At present Seroquel is only approved for the treatment of schizophrenia in adults. The market for treatment of manic depression is estimated at several billions of US dollars. Seroquel is the fastest growing atypical antipsychotic on the market, with global sales of $1.1 bn in 2002. Publication: Chemical Business NewsBase - Dagens Industri Distributed by Financial Times Information Limited - Asia Africa Intelligence Wire <> << Copyright ©2003 Financial Times Limited, All Rights Reserved >>
15 Февраль,2003 | Quetiapine, iloperidone, melperone selectively increase dopamine/acetylcholine - Antipsychotic Drugs
According to recent research from the United States, "preferential increases in both cortical dopamine and acetylcholine release have been proposed to distinguish the atypical antipsychotic drugs clozapine, olanzapine, risperidone, and ziprasidone from typical APDs such as haloperidol. Drug Week via NewsEdge Corporation : According to recent research from the United States, "preferential increases in both cortical dopamine (DA) and acetylcholine (ACh) release have been proposed to distinguish the atypical antipsychotic drugs (APDs) clozapine, olanzapine, risperidone, and ziprasidone from typical APDs such as haloperidol. Although only clozapine and ziprasidone are directly acting 5-HT1A agonists; WAY100635, a selective 5-HT1A antagonist, partially attenuates these atypical APD induced increases in cortical DA release that may be due to combined blockade. However, WAY100635 does not attenuate clozapine induced cortical ACh release. "The present study determined whether quetiapine, iloperidone, and melperone; 5-HT2A/D-2 antagonist atypical APDs, also increase cortical DA and ACh release, and whether these effects are related to 5-HT1A agonism. Quetiapine (30 mg/kg), iloperidone (1-10 mg/kg), and melperone (3-10 mg/kg) increased DA and ACh release in the medial prefrontal cortex (mPFC). Iloperidone (10 mg/kg) and melperone (10 mg/kg), but not quetiapine (30 mg/kg), produced an equivalent or a smaller increase in DA release in the nucleus accumbens (NAC), respectively, compared to the mPFC; whereas none of them increased ACh release in the NAC. WAY100635 (0.2 mg/kg), which alone did not affect DA or ACh release, partially attenuated quetiapine (30 mg/kg), iloperidone (10 mg/kg), and melperone (10 mg/kg) induced DA release in the mPFC. WAY100635 also partially attenuated quetiapine (30 mg/kg) induced ACh release in the mPFC, but not that induced by iloperidone (10 mg/kg) or melperone (10 mg/kg)," wrote J. Ichikawa. The researchers concluded: "These results indicate that quetiapine, iloperidone and melperone preferentially increase DA release in the mPFC, compared to the NAC via a 5-HT1A-related mechanism. However, 5-HT1A agonism may be important only for quetiapine-induced ACh release." Ichikawa and colleagues published their study in Brain Research (Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: Role of 5-HT1A receptor agonism. Brain Res, 2002;956(2):349-357). For additional information, contact J. Ichikawa, Hospital of Psychiatry, 1601 23rd Avenue S, 1st Floor Laboratory, Room 1117, Nashville, TN 37212, USA. To subscribe to the journal Brain Research, contact the publisher: Elsevier Science BV, PO Box 211, 1000 AE Amsterdam, Netherlands. The information in this article comes under the major subject areas of Dopamine, Acetylcholine, Drugs and Antipsychotic Therapy. This article was prepared by Drug Week editors from staff and other reports. <> << Copyright ©2003 NewsRx.com >>
14 Февраль,2003 | Пополнение в разделе Пособия
В разделе пособия для врачей размещены материалы диагностического семинара, посвященного принципам диагностики шизофрении. Ред. коллегия: В. М. Банщиков, В. Я. Гиндикин, Н. М. Жариков, 3. Н. Серебрякова, 1967.
12 Февраль,2003 | Hemoxymed's Diagnostic Test in Development is Useful in Differentiating Patients with Alzheimer's Disease from Patients with Geriatric Major Depre
VERNON HILLS, Ill.-- today announced that the diagnostic test to detect Alzheimer's disease , being developed by its wholly owned subsidiary, Molecular Geriatrics Corporation , is useful to differentiate patients with geriatric major depression from patients with AD. Business Wire via NewsEdge Corporation : VERNON HILLS, Ill.--(BUSINESS WIRE)--Feb. 12, 2003--Hemoxymed, Inc. (OTC BB:HMYD) today announced that the diagnostic test to detect Alzheimer's disease (AD), being developed by its wholly owned subsidiary, Molecular Geriatrics Corporation (MGC), is useful to differentiate patients with geriatric major depression from patients with AD. A study published in the February 2003 issue of the American Journal of Psychiatry concluded that the diagnostic test being developed by MGC measures a potential biological marker that is useful in the differentiation of patients with major geriatric depression from patients with Alzheimer's disease. MGC's diagnostic test measures levels of an abnormally phosphorylated brain protein (tau protein) in cerebrospinal fluid (CSF). Increased CSF concentrations of phosphorylated tau (ptau) protein have been suggested as a biomarker for Alzheimer's disease. "The results of the study reported in the American Journal of Psychiatry indicated that levels of ptau protein were significantly higher in Alzheimer's disease patients than in geriatric major depression patients and healthy comparison subjects. This is significant because differentiation of geriatric major depression from Alzheimer's disease has been hampered due to overlapping symptoms. While memory loss is a sign of AD, in many cases depression may be the cause of the memory loss. Clinicians who can differentiate their patients with AD from those with geriatric major depression have options in treating these patients," said John F. DeBernardis, Ph.D., President and COO of both MGC and Hemoxymed and a co-author of the publication. "We continue to be pleased by the performance of the diagnostic test we are developing to detect Alzheimer's disease," said Bruce N. Barron, Chairman and CEO of both MGC and Hemoxymed. "Based on the results of studies aggregating samples from over 1300 patients, our diagnostic test has been able to consistently differentiate patients with Alzheimer's disease from patients with other neurological diseases, patients with other relevant forms of dementia and normal controls with an overall sensitivity and specificity in the 85% to 95% range. We are currently exploring our options for the final clinical and regulatory development of our AD diagnostic test," concluded Mr. Barron. Molecular Geriatrics Corporation, a wholly owned subsidiary of Hemoxymed, Inc., is engaged in the research and development of a diagnostic to detect Alzheimer's disease and novel therapeutics to treat Alzheimer's disease and cancer. Hemoxymed SAS, the other wholly owned subsidiary of Hemoxymed, Inc., is developing a drug delivery technology that involves a novel therapeutic process designed to increase tissue oxygenation. NOTE: "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: This news release contains certain forward-looking statements based on the hopes and expectations of the management of Hemoxymed and MGC. There are certain key factors that could cause future results to differ from those anticipated by the companies' managements and Boards of Directors including, but not limited to, the risk that they do not complete the development of the diagnostic test to detect Alzheimer's disease or any of their other proposed products. CONTACT: Hemoxymed, Inc. David Ellison, 847/573-8000 KEYWORD: ILLINOIS INDUSTRY KEYWORD: MEDICAL PHARMACEUTICAL SOURCE: Hemoxymed, Inc. Today's News On The Net - Business Wire's full file on the Internet with Hyperlinks to your home page. URL: http://www.businesswire.com <> << Copyright ©2003 Business Wire >>
| Главная | Структура центра | История НЦПЗ | Совет молодых ученых | Костромские школы молодых ученых | Новости | Профсоюз | Правовые документы | Вакансии | О сайте | Научная работа | Научные отделы и лаборатории | Публикации сотрудников | Диссертационный совет | Авторефераты диссертаций | Музей НЦПЗ | Для научных сотрудников НЦПЗ | Центр коллективного пользования «Терапевтический лекарственный мониторинг» | Образовательная деятельность | Ординатура | Аспирантура | Дополнительное профессиональное образование | Студенческий научный кружок | Нормативные документы | Платные образовательные услуги | Информация для обучающихся в ординатуре и аспирантуре | Лечебный процесс | Клинические отделения | Условия и порядок стационирования | Прейскурант платных медицинских услуг | Перечень заболеваний | Отзывы о работе клиники | Клиника (фотогалерея) | Библиотека | Научная литература для специалистов | Материалы конференций | Авторефераты диссертаций | Пособия для врачей | Психометрические шкалы | Болезнь и творчество | Галерея | Журнал «Психиатрия» | Перечень тематических журналов, рекомендованных ВАК | Перечень тематических журналов в международных БД | РИНЦ | Russian Science Citation Index (RSCI) | Полезные ссылки | Журнал «Психиатрия» | Неспециалистам | Контакты